First human tests begin for new Sjogren's syndrome drug
NCT ID NCT06484855
Summary
This early-stage study tested a new drug called IBI355 in 30 adults with primary Sjogren's syndrome, an autoimmune disease that causes dry eyes and mouth. The main goal was to check how safe the drug is and how the body processes it when given in increasing doses. Researchers also looked for any immune reactions against the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230001, China
Conditions
Explore the condition pages connected to this study.